)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Gerresheimer
Gerresheimer (GXI) investor relations material
Gerresheimer Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 TU earnings summary30 Oct, 2026
Executive summary
Q3 revenue rose 8% YoY to €605m; adjusted EBITDA was €103m versus €106m adjusted in Q3 2025, with margin at 17.1% versus 19.0%.
9M revenue was €1.7bn; adjusted EBITDA declined to €272m from €331m, reflecting inventory reductions and weaker Tubular Glass and Moulded Glass performance.
Q3 and 9M revenue growth was supported primarily by Containment & Delivery Systems and higher demand for drug delivery devices.
Priorities include FY26 guidance delivery, cash and inventory management, divestitures, debt reduction and operational transformation.
Financial highlights
Q3 revenue was €605m, up €46m YoY and €26m QoQ; adjusted EBITDA was €103m.
Q3 free cash flow before M&A was -€20m versus €21m in Q3 2025; net CapEx was €56m versus €64m.
Inventory fell €20m in Q3 versus a €14m build in Q3 2025, weighing on comparative EBITDA.
9M free cash flow before M&A was -€141m versus -€119m; net CapEx was €149m versus €237m.
Outlook and guidance
FY26 guidance remains unchanged: revenue €2.3bn–€2.35bn, organic adjusted EBITDA margin 17%–18%, and free cash flow before M&A of -€50m to -€100m.
Stronger Q4 trading and customary customer and supplier settlements are expected to support EBITDA and positive free cash flow before M&A.
No significant further inventory reduction is anticipated in Q4; most of the Moulded Glass inventory impact is considered past.
FY27 energy costs are expected to be a headwind, especially in Moulded Glass; hedging is ~80% for 2026 and below 50% for 2027, with efficiency and pricing actions as mitigations.
GTO targets €50m–€70m annualized EBITDA improvement, with implementation in 2026–27 and full run-rate impact expected in 2028.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Gerresheimer
- Profitable FY growth and rising investment underpin ambitious biologics-led targets.GXI
Q4 2023 - Q2 2026 adjusted EBITDA jumped over 50% sequentially, led by operational recovery and divestitures.GXIQ2 2026 TU
- Transformation, compliance, and portfolio focus drive financial recovery and future growth.GXIAGM 2026
- Cash discipline, asset sales, and transformation drove best Q1 free cash flow since 2019.GXIQ1 2026
- FY25 revenue up 17% to EUR 2.3bn, but margin and cash flow declined amid restructuring.GXIQ4 2025
- 2024 guidance cut as vial demand lags and US plant flooding impacts results.GXIQ3 2024 TU
- Q2 2024 showed resilient results, strong Plastics & Devices, and a major pharma acquisition.GXIQ2 2024
- Bormioli Pharma deal lifts revenue, but net income falls and leverage rises to 3.97x.GXIQ1 2025
- Strong Q4 growth and Bormioli integration drive robust 2025 outlook and margin expansion.GXIQ4 2024
Next Gerresheimer earnings date
Q3 20264 Dec, 2026
Gerresheimer
Next Gerresheimer earnings date
Q3 20264 Dec, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Gerresheimer AG is a Germany-based manufacturer of primary packaging products and drug delivery devices for the pharmaceutical and healthcare industries. The company produces glass and plastic containers, syringes, inhalers, and other medical packaging solutions. It operates production facilities across Europe, the Americas, and Asia. Gerresheimer AG is headquartered in Düsseldorf, Germany, and its shares are listed on the XETRA.